Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C
1 other identifier
interventional
15
1 country
1
Brief Summary
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
Started Jan 2008
Shorter than P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedFirst Submitted
Initial submission to the registry
February 12, 2008
CompletedFirst Posted
Study publicly available on registry
February 22, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2009
CompletedResults Posted
Study results publicly available
October 19, 2012
CompletedJanuary 6, 2026
December 1, 2025
1.1 years
February 12, 2008
September 19, 2012
December 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration
24 Weeks After Completion of Drug Administration (dosing period is 24 Weeks) or drug withdrawal. The subjects were assessed at 24 weeks following the last dose of study drug.
Study Arms (1)
MP-424
EXPERIMENTALInterventions
Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
Eligibility Criteria
You may qualify if:
- Patients diagnosed with genotype 1b chronic hepatitis C
- Patients naive to the concomitant medications with interferon
You may not qualify if:
- Patients diagnosed with decompensated cirrhosis
- Patients diagnosed with positive HBs antigen in the test
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tanabe Pharma Corporationlead
- Vertex Pharmaceuticals Incorporatedcollaborator
Study Sites (1)
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
Related Publications (1)
Toyota J, Ozeki I, Karino Y, Asahina Y, Izumi N, Takahashi S, Kawakami Y, Chayama K, Kamiya N, Aoki K, Yamada I, Suzuki Y, Suzuki F, Kumada H. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat. 2013 Mar;20(3):167-73. doi: 10.1111/j.1365-2893.2012.01640.x. Epub 2012 Jul 13.
PMID: 23383655RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Clinical Trials, Information Desk
- Organization
- Tanabe Pharma Corporation
Study Officials
- PRINCIPAL INVESTIGATOR
Fumitaka Suzuki, MD
Department of Hepatology, Toranomon Hospital
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 12, 2008
First Posted
February 22, 2008
Study Start
January 1, 2008
Primary Completion
February 1, 2009
Study Completion
February 1, 2009
Last Updated
January 6, 2026
Results First Posted
October 19, 2012
Record last verified: 2025-12